OTHER FUNCTIONS TARGET SPECIFIC AND DRUG LOADED IRON OXIDE NANOPARTICLES FOR CANCER IMAGING AND THERAPY.

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$1,200,000.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
N44CO120029
Agency Tracking Number:
N44CO120029
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
OCEAN NANOTECH, LLC
OCEAN NANOTECH, LLC, SPRINGDALE, AR, 72764-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
155516987
Principal Investigator
 ANDREW WANG
 (479) 236-7147
 AWANG@OCEANNANOTECH.COM
Business Contact
 ANDREW WANG
Phone: (479) 236-7147
Email: AWANG@OCEANNANOTECH.COM
Research Institution
 Stub
Abstract
Breast cancer is the most common type of cancer and the second leading cause of cancer death among women with more than one million new cases and 370,000 deaths worldwide yearly. Chemotherapy drugs, such as Doxorubicin, have been used in both pre- and post-operative adjuvant therapy or as the main therapeutic option for breast cancer patients with metastatic disease. Although recent advances in the combination of chemotherapy drugs have improved survival for breast cancer patients, a high percentage of patients develop resistance to chemotherapeutic agents and fail treatment. Therefore, novel approaches for the effective treatment of breast cancer are urgently needed to improve the therapeutic response. This project aims to develop a Doxorubicin loaded and target specific magnetic iron oxide nanoparticle (IONP) platform for targeted therapy of breast cancer. The proposed nanodrug can be systemically delivered and selectively accumulated at the primary and metastatic tumor sites and subsequently internalized into breast cancer cells via endocytosis. Selective enrichment of the IONP in tumor cells and the tumor environment produces strong MRI contrast for the detection of drug delivery and response in the tumor lesions by MR imaging. After demonstration of the feasibility that the engineered nanodrug can target the tumor in an animal model, the goal of this SBIR Phase II project is to extend the investigation of the successes in the Phase I study and move closer to translating this platform into preclinical trials and commercialization by further optimizing the targeted theranostic nanodrug platform for efficacy, biodistribution, toxicity, pharmacokinetics/pharmacodynamic studies, and future clinical trials.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government